Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib + Fulvestrant in Advanced Breast Cancer
NCT06764186Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capivasertib in breast cancer, sponsored by AstraZeneca. Started Jan 2025; status: active, not recruiting.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06764186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764186.